Twinning: Collaboration Improves Pediatric Leukemia Care in LMICs
Researchers sought to determine whether a “twinning” program would improve pediatric ALL outcomes in LMICs.
Leukemia
LEUKEMIA
FEATURE
LATEST ARTICLES
Acalabrutinib Has Superior Safety Profile to Ibrutinib in Previously Treated CLL
Researchers sought to determine whether acalabrutinib would be superior to ibrutinib in patients with previously treated CLL.
Patients With MM and CLL Report Blood Cancer Coach App Helpful
A feasibility pilot assessed acceptability of mobile app for symptom management in multiple myeloma and chronic lymphocytic leukemia.
CLL Treatment Affects ICI Efficacy in Patients With Melanoma and CLL
Treating advanced melanoma with immune checkpoint inhibitors can be safe and effective in patients with concomitant CLL, a study suggests.
Study May Explain Why CLL Patients Respond Poorly to COVID-19 Vaccines
New research may explain why patients with CLL tend to respond poorly to COVID-19 vaccination.
Liso-Cel Shows Efficacy in CLL/SLL in TRANSCEND CLL 004 Study
Researchers sought to determine whether liso-cel would induce clinical responses in patients with CLL/SLL.
Ibrutinib Plus Venetoclax Improved Outcomes Compared With Chlorambucil Plus Obinutuzumab in CLL
Researchers sought to determine whether combination ibrutinib and venetoclax would improve outcomes in patients with CLL compared with chlorambucil plus obinutuzumab.
Fixed-Duration Ibrutinib-Venetoclax Appears Effective in High-Risk CLL
Fixed-duration ibrutinib and venetoclax produces similar outcomes in CLL patients who have high-risk features and those who don’t, data suggest.
Ibrutinib Improves PFS, Not OS in High-Risk CLL
Ibrutinib does not improve overall survival in patients with treatment-naïve chronic lymphocytic leukemia at high risk of progression, a phase 3 trial suggests.
Venetoclax Plus Obinutuzumab Improves Outcomes in CLL
Researchers sought to determine whether treating CLL with venetoclax plus obinutuzumab with or without ibrutinib would lead to improved survival.
METTL3 Controls Splicing Factor Abundance and Cell Growth in CLL
Researchers sought to determine the role of METTL3 in disease progression for patients with CLL.
COVID-19 Deaths May Have Interfered With Results of CLL Trial
Researchers investigated whether adding venetoclax to ibrutinib and obinutuzumab would improve survival and allow for discontinuation of treatment in older patients with CLL.
Early Trial Data Show Promising Results for GM-CSF Blockade in CMML
Researchers are seeking to determine whether adding lenzilumab to standard-of-care treatment will improve outcomes in patients with CMML.
Ianalumab, Ibrutinib Combination Promising in Chronic Lymphocytic Leukemia
Researchers sought to determine whether combination therapy with ianalumab and ibrutinib would have efficacy in patients with CLL.
Improving Risk Stratification in Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia in Children
Researchers sought to better discriminate true MRD positivity for risk stratification in chronic lymphocytic leukemia and acute lymphoblastic leukemia in children.
Fixed Venetoclax Dosing May Not Be Feasible for All Patients With CLL
Researchers sought to determine whether patients with CLL/SLL would be able to maintain fixed dosing schedule of venetoclax-based regimens in their treatments.
Exercise Alters T-Cell Ratio and Improves Physical Functioning in CLL
Researchers sought to determine the impact of exercise done at home by patients with chronic lymphocytic leukemia.
Trial Evaluating Lisocabtagene Maraleucel for Relapsed/Refractory CLL Meets Endpoint
Lisocabtagene maraleucel is a CD19-directed genetically modified autologous T cell immunotherapy.
Brukinsa Gains Approval for Chronic Lymphocytic Leukemia
The approval was based on data from the phase 3 SEQUOIA and ALPINE studies in patients with CLL/SLL.
Zanubrutinib Outperforms Ibrutinib in Relapsed/Refractory CLL/SLL
Zanubrutinib prolongs progression-free survival, when compared with ibrutinib, in patients with relapsed/refractory CLL/SLL, a phase 3 trial suggests.
MRD-Guided Treatment Intensification Feasible in R/R Chronic Lymphocytic Leukemia
Researchers sought to determine whether uMRD could determine discontinuation of venetoclax or the addition of ibrutinib in patients with R/R CLL.
Addition of Anti-CD19 CAR-T to Ibrutinib Yields Deep, Durable Remissions in Chronic Lymphocytic Leukemia
Researchers sought to determine whether adding anti-CD19 CAR-T cells to ibrutinib would improve remission rates in CLL.
Zanubrutinib May Produce Better Outcomes Than Ibrutinib in Rel/Ref CLL, SLL
Zanubrutinib may produce superior outcomes to ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Current and Emerging BTK Inhibitors for Chronic Lymphocytic Leukemia
Researchers sought to determine the landscape of BTK inhibitors for treating patients with CLL.
Surface IgM Signaling Capacity Associated With Ibrutinib Resistance in Chronic Lymphocytic Leukemia
Researchers sought to determine whether IgM levels would impact treatment responsiveness to ibrutinib in patients with CLL.
Triplet Falls Short in Relapsed/Refractory Chronic Lymphocytic Leukemia
Combination acalabrutinib, obinutuzumab, and venetoclax did not meet the prespecified activity threshold in the CLL2-BAAG trial.
Long-Term Follow-Up Shows Continued Survival Benefit With Ibrutinib/Rituximab in Chronic Lymphocytic Leukemia
Researchers sought to determine whether there was a sustained benefit for patients with CLL receiving treatment with ibrutinib plus rituximab.
PFS Not Associated With 1-Year Depth of Response to Ibrutinib in Chronic Lymphocytic Leukemia
Researchers sought to determine whether there was a difference in PFS based on depth of response with ibrutinib at 1 year in patients with CLL.
Ferroptosis-Related Gene Expression May Predict Outcomes in Chronic Lymphocytic Leukemia
Researchers sought to determine whether there was an association between ferroptosis-related genes and prognosis for patients with CLL.
FDA Warns of Increased Side Effects, Death Risk With Duvelisib
Copiktra is an oral inhibitor of phosphoinositide 3-kinase.
Bacterial Coinfection Associated With Poor COVID-19 Outcomes in Chronic Lymphocytic Leukemia
Researchers sought to determine the case fatality rate in patients with CLL who were infected with SARS-CoV-2.
TAp63 Expression Levels May Drive Disease Aggressiveness in Chronic Lymphocytic Leukemia
Researchers sought to determine whether there was a link between TAp63 and disease aggressiveness in patients with CLL.
Clinical Advantages: Targeting BTK in CLL
Chronic lymphocytic leukemia (CLL) is a chronic incurable mature B-cell neoplasm that often does not require immediate treatment; however, when patients experience symptoms, such as anemia, cytopenias, or bulky lymphadenopathy, therapy is required. During a presentation at the 2022 Oncology Nurse Advisor Summit, Laura J. Zitella, MS, RN, ACNP-BC, AOCN, an associate clinical professor at…
Moderna COVID-19 Vaccine May Be More Effective in CLL Patients
Patients with CLL were significantly more likely to have an antibody response to the Moderna vaccine than to the Pfizer-BioNTech vaccine.
Venetoclax Plus Dose-Adjusted R-EPOCH Yields Deep, Durable Responses in Patients With Richter Syndrome
Researchers sought to determine whether adding venetoclax to R-EPOCH would induce durable responses in patients with Richter syndrome.
Treatment With Obinutuzumab Makes Earlier Ibrutinib Discontinuation Possible in Chronic Lymphocytic Leukemia
Researchers sought to determine whether adding obinutuzumab to ibrutinib for patients with CLL would permit earlier ibrutinib discontinuation.
CAR-T Therapy Ushering in a New Era of Precision Medicine for Patients With Chronic Lymphocytic Leukemia
Researchers are working towards developing CAR-T therapy to provide longer and more durable responses for patients with CLL.
Third COVID-19 Vaccine Dose May Induce Response in Subset of Patients With Chronic Lymphocytic Leukemia
Researchers sought to determine whether a third dose of the BNT162b2 mRNA vaccine against COVID-19 may induce an antibody response in patients with CLL or SLL.
Less Intensive Monitoring of Venetoclax May be Safe in Low-Risk CLL
A retrospective review of data from patients with CLL demonstrated varied adherence to guidelines for ramp up initiation and laboratory monitoring.
Age Is Not an Independent Predictor of Outcomes in Chronic Lymphocytic Leukemia Treated With Ibrutinib
Researchers sought to determine whether age impacts survival in patients with CLL undergoing treatment with ibrutinib.
Prognostic Index May ID CLL Patients Who Will Not Need Treatment
Novel prognostic index CLL-WONT identifies patients with chronic lymphocytic leukemia who are at low risk for ever requiring treatment
MRD Status May Not Predict PFS for Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib
Researchers sought to determine whether MRD negativity could predict PFS in patients with CLL treated with ibrutinib.
Ibrutinib Not Recommended Over ‘Watch and Wait’ in Asymptomatic, Early CLL
Ibrutinib improved event-free survival, but its effect on overall survival is unclear.
CLL Treatment May Increase Risk of Death From COVID-19
There were no significant differences by treatment type.
Ponatinib Yields Benefits Across 3 Dosage Regimens in Chronic-Phase Chronic Myeloid Leukemia
Researchers sought to determine whether different doses of ponatinib would have benefit for patients with resistant chronic-phase chronic myeloid leukemia.
MRD Dynamics After Fixed-Duration Treatment in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Researchers sought to determine whether MRD would improve after fixed-duration treatment with venetoclax and obinutuzumab therapy in patients with CLL.
GST Polymorphisms Are Associated With Risk of B-Cell Acute Lymphocytic Leukemia
Researchers sought to determine the impact of GST polymorphisms on the risk of B-ALL.
Progression After BTK Inhibitor and Venetoclax Progression Linked With Poor Outcomes in Chronic Lymphocytic Leukemia
Researchers sought to determine whether patients with CLL whose disease develops resistance to both BTK and BCL2 inhibition have a poor prognosis.
F2-ISoP Levels in CSF a Potential Biomarker of Therapy-Related Cognitive Outcomes in Children With ALL
Researchers sought to determine if F2-ISoP levels could be a biomarker for cognitive dysfunction in children with ALL.
Cell-in-Cell Sheltering May Have Implications in Drug Resistance
Researchers sought to determine whether cell-in-cell interactions would have a role in drug resistance.
Acalabrutinib, Venetoclax, Obinutuzumab Shows Promise as Frontline Therapy for Chronic Lymphocytic Leukemia
Researchers sought to determine whether acalabrutinib, venetoclax, and obinutuzumab would be a helpful option for frontline treatment of CLL.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Leukemia
Loading... 
Loading...